In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
In two weeks' time, independent mutual fund directors will gather in New York to discuss issues related board composition and diversity in the boardroom. The directors—and ...
Investment Company Institute CEO Eric Pan came out swinging on Tuesday, delivering keynote remarks to 2024 Investment Management Conference attendees in which he railed against "over-regulation" and vowed ...
A senior member of the Securities and Exchange Commission's Division of Investment Management on Monday indicated to mutual fund industry professionals that the Commission will not ...
Today is International Women's Day, and there's plenty to celebrate in the mutual fund governance space. Women have made strides in recent years in getting into ...